Johnson & Johnson touts Phase 3 win for TALVEY combination in relapsed multiple myeloma
Results from the MonumenTAL-3 study reported by Johnson & Johnson indicate that combining TALVEY with DARZALEX FASPRO improved outcomes versus standard regimens for patients with relapsed or refractory multiple myeloma, according to a report carried by Yahoo Finance.